The pooled SMD was 0.81 (95% CI: 0.21‐1.40; P = .008), indicating that the level of IL‐6 (Figure 2A) in the peripheral blood of glioma patients was significantly higher than that of the normal control group. Here, IL6 is linked to central nervous system cancer.